Glepaglutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Glepaglutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Glepaglutide can convert its Synthetic peptide profile and GLP-2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Glepaglutide (query alias: Glepaglutide) |
|---|---|
| Modality / target | Synthetic peptide; GLP-2R; GLP-2R agonists |
| Highest global status | NDA/BLA |
| Originator | Zealand Pharma A/S |
| Active developers | Zealand Pharma A/S, Zealand Pharma U.S., Inc. |
The MCP disease footprint includes Short Bowel Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04881825 | Phase 3 | Active, not recruiting | 129 | Incidence and type of Adverse Events (AEs) |
| NCT07197944 | Phase 3 | Recruiting | 90 | Change in weekly Parenteral Support (PS) volume |
| NCT07228403 | Phase 3 | Enrolling by invitation | 35 | Number of treatment emergent adverse events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Weekly PS volumes = -2.85 L/wk ; Weekly PS volumes = -5.13 L/wk
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
Phase 3; n=106; evaluation: not stated. Reported fields: Change in Weekly Parenteral Support (PS) Volume(Least Squares Mean) = -5.13 L/week (95% Confidence Interval, -6.24 to -4.02); Change in Weekly Parenteral Support (PS) Volume(Least Squares Mean) = -3.76 L/week (95% Confidence Interval, -4.96 to -2.56); Change in Weekly Parenteral Support (PS) Volume(Least Squares Mean): Difference to Placebo = -2.28(95% CI, -3.83 to -0.73), P-Value = 0.0039; Difference to Placebo = -0.91(95% CI, -2.52 to 0.71), P-Value = 0.2700
EFFECT OF GLEPAGLUTIDE, A LONG-ACTING GLP-2 ANALOG, ON HEPATIC, RENAL AND BONE MARKERS IN PATIENTS WITH SHORT BOWEL SYNDROME: RESULTS OF EASE SBS-1 PHASE 3 TRIAL
Phase 3; n=106; evaluation: Positive. Reported fields: Bone markers = No difference between active treatment and placebo was observed for change from baseline to Week 24 for the bone markers
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Glepaglutide addresses Short Bowel Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 11 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GLP-2R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-01 | Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog) | Phase 2 | US$75.0M upfront; US$1,185.0M milestones |
| 2024-06-24 | Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment | Preclinical | Financial terms not disclosed |
| 2023-12-21 | 百图生科与志道生物合作 GLP-2 新适应症挖掘及管线开发 | Discovery | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
